209 related articles for article (PubMed ID: 38048133)
1. Mortality and Morbidity Among Individuals With Hypertension Receiving a Diuretic, ACE Inhibitor, or Calcium Channel Blocker: A Secondary Analysis of a Randomized Clinical Trial.
Yamal JM; Martinez J; Osani MC; Du XL; Simpson LM; Davis BR
JAMA Netw Open; 2023 Dec; 6(12):e2344998. PubMed ID: 38048133
[TBL] [Abstract][Full Text] [Related]
2. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
JAMA; 2002 Dec; 288(23):2981-97. PubMed ID: 12479763
[TBL] [Abstract][Full Text] [Related]
3. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
Wright JT; Dunn JK; Cutler JA; Davis BR; Cushman WC; Ford CE; Haywood LJ; Leenen FH; Margolis KL; Papademetriou V; Probstfield JL; Whelton PK; Habib GB;
JAMA; 2005 Apr; 293(13):1595-608. PubMed ID: 15811979
[TBL] [Abstract][Full Text] [Related]
4. First-line diuretics versus other classes of antihypertensive drugs for hypertension.
Reinhart M; Puil L; Salzwedel DM; Wright JM
Cochrane Database Syst Rev; 2023 Jul; 7(7):CD008161. PubMed ID: 37439548
[TBL] [Abstract][Full Text] [Related]
5. Association between cardiovascular outcomes and antihypertensive drug treatment in older women.
Wassertheil-Smoller S; Psaty B; Greenland P; Oberman A; Kotchen T; Mouton C; Black H; Aragaki A; Trevisan M
JAMA; 2004 Dec; 292(23):2849-59. PubMed ID: 15598916
[TBL] [Abstract][Full Text] [Related]
6. First-line drugs for hypertension.
Wright JM; Musini VM; Gill R
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD001841. PubMed ID: 29667175
[TBL] [Abstract][Full Text] [Related]
7. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
JAMA; 2000 Apr; 283(15):1967-75. PubMed ID: 10789664
[TBL] [Abstract][Full Text] [Related]
8. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
Chen YJ; Li LJ; Tang WL; Song JY; Qiu R; Li Q; Xue H; Wright JM
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008170. PubMed ID: 30480768
[TBL] [Abstract][Full Text] [Related]
9. Mortality and morbidity during and after Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: results by sex.
Oparil S; Davis BR; Cushman WC; Ford CE; Furberg CD; Habib GB; Haywood LJ; Margolis K; Probstfield JL; Whelton PK; Wright JT;
Hypertension; 2013 May; 61(5):977-86. PubMed ID: 23529173
[TBL] [Abstract][Full Text] [Related]
10. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.
Black HR; Elliott WJ; Grandits G; Grambsch P; Lucente T; White WB; Neaton JD; Grimm RH; Hansson L; Lacourciere Y; Muller J; Sleight P; Weber MA; Williams G; Wittes J; Zanchetti A; Anders RJ;
JAMA; 2003 Apr 23-30; 289(16):2073-82. PubMed ID: 12709465
[TBL] [Abstract][Full Text] [Related]
11. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Barzilay JI; Davis BR; Cutler JA; Pressel SL; Whelton PK; Basile J; Margolis KL; Ong ST; Sadler LS; Summerson J;
Arch Intern Med; 2006 Nov; 166(20):2191-201. PubMed ID: 17101936
[TBL] [Abstract][Full Text] [Related]
12. Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study.
Barzilay JI; Davis BR; Pressel SL; Cutler JA; Einhorn PT; Black HR; Cushman WC; Ford CE; Margolis KL; Moloo J; Oparil S; Piller LB; Simmons DL; Sweeney ME; Whelton PK; Wong ND; Wright JT;
Circ Cardiovasc Qual Outcomes; 2012 Mar; 5(2):153-62. PubMed ID: 22396585
[TBL] [Abstract][Full Text] [Related]
13. Association of 3 Different Antihypertensive Medications With Hip and Pelvic Fracture Risk in Older Adults: Secondary Analysis of a Randomized Clinical Trial.
Puttnam R; Davis BR; Pressel SL; Whelton PK; Cushman WC; Louis GT; Margolis KL; Oparil S; Williamson J; Ghosh A; Einhorn PT; Barzilay JI;
JAMA Intern Med; 2017 Jan; 177(1):67-76. PubMed ID: 27893045
[TBL] [Abstract][Full Text] [Related]
14. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
Leenen FH; Nwachuku CE; Black HR; Cushman WC; Davis BR; Simpson LM; Alderman MH; Atlas SA; Basile JN; Cuyjet AB; Dart R; Felicetta JV; Grimm RH; Haywood LJ; Jafri SZ; Proschan MA; Thadani U; Whelton PK; Wright JT;
Hypertension; 2006 Sep; 48(3):374-84. PubMed ID: 16864749
[TBL] [Abstract][Full Text] [Related]
15. Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study.
Lynch AI; Boerwinkle E; Davis BR; Ford CE; Eckfeldt JH; Leiendecker-Foster C; Arnett DK
Pharmacogenet Genomics; 2009 Jun; 19(6):415-21. PubMed ID: 19352213
[TBL] [Abstract][Full Text] [Related]
16. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
[TBL] [Abstract][Full Text] [Related]
17. [Clinical study of the month. Which initial antihypertensive? Results from the ALLHAT trial].
Scheen AJ; Krzesinski JM
Rev Med Liege; 2003 Jan; 58(1):47-52. PubMed ID: 12647599
[TBL] [Abstract][Full Text] [Related]
18. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
[TBL] [Abstract][Full Text] [Related]
19. Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension.
Musini VM; Nazer M; Bassett K; Wright JM
Cochrane Database Syst Rev; 2014 May; 2014(5):CD003824. PubMed ID: 24869750
[TBL] [Abstract][Full Text] [Related]
20. The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy.
Hackam DG; Khan NA; Hemmelgarn BR; Rabkin SW; Touyz RM; Campbell NR; Padwal R; Campbell TS; Lindsay MP; Hill MD; Quinn RR; Mahon JL; Herman RJ; Schiffrin EL; Ruzicka M; Larochelle P; Feldman RD; Lebel M; Poirier L; Arnold JM; Moe GW; Howlett JG; Trudeau L; Bacon SL; Petrella RJ; Milot A; Stone JA; Drouin D; Boulanger JM; Sharma M; Hamet P; Fodor G; Dresser GK; Carruthers SG; Pylypchuk G; Burgess ED; Burns KD; Vallée M; Prasad GV; Gilbert RE; Leiter LA; Jones C; Ogilvie RI; Woo V; McFarlane PA; Hegele RA; Tobe SW;
Can J Cardiol; 2010 May; 26(5):249-58. PubMed ID: 20485689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
